Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
postpartum depression
Pharma
Beleaguered Sage bought for $561M
Supernus is buying Sage Therapeutics for $561 million, hoping that it can transform a new postpartum depression drug into a “standard of care."
Kevin Dunleavy
Jun 16, 2025 11:52am
Sage 'highly encouraged' by Zurzuvae launch with Biogen
Feb 14, 2024 1:21pm
After 40% reduction in workforce, Sage will shift to smaller HQ
Jan 25, 2024 10:55am
Sage, Biogen call an audible on pricing strategy for Zurzuvae
Nov 7, 2023 3:24pm
Biogen, Sage receive bittersweet news from the FDA
Aug 7, 2023 10:01am
